Form 4: Avidity CMO Exercises Options, Sells Shares

Avidity Biosciences' Chief Medical Officer, Steven George Hughes, executed a pre-arranged transaction, exercising stock options and selling an equal number of common shares.

Summary

• Steven George Hughes, Chief Medical Officer of Avidity Biosciences, Inc. (RNA), reported changes in beneficial ownership.
• On September 22, 2025, Mr. Hughes acquired 2,208 shares of common stock through the exercise of stock options at a price of $10.16 per share.
• Concurrently, on September 22, 2025, he disposed of 2,208 shares of common stock at a price of $40.58 per share.
• Both the exercise and sale transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on June 12, 2024.
• Following these transactions, Mr. Hughes directly beneficially owns 38,867 shares of common stock.
• He also directly beneficially owns 70,667 derivative securities (stock options) after the reported transaction.
• The exercised option was granted on January 20, 2024, and vests in equal monthly installments of 2,208 shares until fully vested on January 20, 2028, with an expiration date of January 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine, pre-planned insider transaction (exercise and sell) under a 10b5-1 plan, which is a common liquidity event for executives. The significant profit margin on the options is positive for the insider, but the transaction itself does not indicate a change in company fundamentals.

Positives

• The Chief Medical Officer realized a significant profit from the option exercise and subsequent sale, with shares sold at $40.58 compared to an exercise price of $10.16.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-planned liquidity event rather than a reaction to recent material non-public information.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, although this appears to be a routine 'cash-out' of exercised options.

Future Outlook

This filing does not contain specific forward-looking statements or guidance regarding the company's future performance or outlook. It solely reports an insider transaction.

Industry Context

This Form 4 filing is specific to an insider transaction at Avidity Biosciences and does not provide broader industry context or trends. Insider transactions are common across all industries as executives manage their equity compensation.

Corporate Governance

Stakeholder Impact

• Shareholders may note the Chief Medical Officer's profitable exercise and sale of shares, which is a common occurrence for executives managing their equity compensation.
• The transaction's execution under a 10b5-1 plan provides transparency regarding the insider's trading activities.

Next Steps

• The remaining stock options will continue to vest in monthly installments until fully vested on January 20, 2028.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise of options and sale of shares) by the Chief Medical Officer. The transaction was executed under a Rule 10b5-1 plan, indicating it was not based on new material non-public information. While the insider realized a significant profit, this is a common liquidity event for executives and does not inherently signal a change in the company's fundamental prospects or warrant a change in investment recommendation based solely on this filing. Investors should hold and monitor broader company performance and news.

Keywords

Avidity Biosciences, RNA, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Steven George Hughes, Chief Medical Officer, 10b5-1 Plan